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Puriﬁed virionsGlycoprotein 3 (GP3) is a highly glycosylated PRRSV envelope protein which has been reported as being
present in the virions of PRRSV type I, while missing in the type II PRRSV (US) virions. We herein present
evidence that GP3 is indeed incorporated in the virus particles of a North American strain of PRRSV (FL12), at
a density that is consistent with the minor structural role assigned to GP3 in members of the Arterivirus
genus. Two 15aa peptides corresponding to two different immunodominant linear epitopes of GP3 derived
from the North American strain of PRRSV (FL12) were used as antigen to generate a rabbit monospeciﬁc
antiserum to this protein. The speciﬁcity of this anti-GP3 antiserum was conﬁrmed by radioimmunopre-
cipitation (RIP) assay using BHK-21 cells transfected with GP3 expressing plasmid, MARC-145 cells infected
with FL12 PRRSV, as well as by confocal microscopy on PRRSV-infected MARC-145 cells. To test if GP3 is a
structural component of the virion, 35S-labelled PRRSV virions were pelleted through a 30% sucrose cushion,
followed by a second round of puriﬁcation on a sucrose gradient (20–60%). Virions were detected in speciﬁc
gradient fractions by radioactive counts and further conﬁrmed by viral infectivity assay in MARC 145 cells.
The GP3 was detected in gradient fractions containing puriﬁed virions by RIP using anti-GP3 antiserum.
Predictably, the GP3 was less abundant in puriﬁed virions than other major structural envelope proteins such
as GP5 and M. Further evidence of the presence of GP3 at the level of PRRSV FL12 envelope was obtained by
immunogold staining of puriﬁed virions from the supernatant of infected cells with anti-GP3 antiserum.
Taken together, these results indicate that GP3 is a minor structural component of the PRRSV type II (FL12
strain) virion, as had been previously described for PRRSV type I.© 2009 Elsevier Inc. All rights reserved.IntroductionPorcine reproductive and respiratory syndrome (PRRS) is char-
acterized by reproductive failure in pregnant sows and respiratory
distress in piglets and growing pigs, being considered one of the most
important viral diseases of pigs in countries with extensive swine
industry (Neumann et al., 2005). The disease is caused by PRRS virus
(PRRSV), whichwas ﬁrst isolated in Europe and then in the US (Collins
et al., 1992). PRRSV is a single stranded RNA virus belonging to the
family Arteriviridae, genus Arterivirus (Meulenberg, 2000). Two
distinct serotypes of PRRV are recognized, type I (European) and
type II (US), both exhibiting a signiﬁcant degree of genetic and
antigenic heterogeneity while maintaining identical pathobiological
phenotypes (Snijder and Meulenberg, 2001). The viral genome is
approximately 15.0 kb in length and contains nine open reading
frames ﬂanked by untranslated regions (UTRs) at the 5′- and 3′-end
(Meulenberg, 2000). ORFs 1a and 1b encode for non-structural
polypeptides with replicase-associated activities whereas ORFs 2–7ll rights reserved.are translated from a nested set of subgenomic RNA (sgRNA) encoding
the structural proteins (Snijder and Meulenberg, 2001). The major
structural proteins include glycoprotein 5 (GP5), M and N (encoded by
ORFs 5, 6 and 7) while the minor structural proteins include GP2, GP3
and GP4 (encoded by ORFs 2a, 3 and 4 respectively) and the small E
protein (encoded by ORF 2b) (Snijder and Meulenberg, 2001; Wu et
al., 2005). Analyses of puriﬁed virions of European strains of PRRSV
have conﬁrmed that six of these PRRSV proteins are authentic
structural proteins, these are: the four glycoproteins: GP2a, GP3,
GP4 and GP5; a nonglycosylated membrane protein M and the
nucleocapsid protein N (Dea et al., 2000). On the other hand, recent
ﬁndings have demonstrated that 2b protein, expressed from a second
ORF entirely contained within ORF2, is also a minor structural
component of PRRSV (Wu et al., 2001, 2005). The structural nature
of GP3 is still controversial, as there is conﬂicting data regarding its
presence as a constituent of the envelope of virus particles. It has been
convincingly demonstrated that GP3 is a 45- to 50-kDa structural
protein of the PRRSV LV (type I or European) strain (Meulenberg et al.,
1995). However, the GP3 has been reported as being a non-structural
protein of the PRRSV type II IAF-Klop strain, with a subset of viral GP3
being released into the cell culture medium as a non-virion associated
Fig. 1. Radioimmunoprecipitation with a rabbit monospeciﬁc GP3 antiserum. A)
Immunoprecipitation analysis of GP3 expressed in BHK-21 cells (lane 2). Cells
transfected with an empty vector (lane 1). B) MARC145 cells infected with PRRSV
FL12 (lane 2). Mock-infected cells (lane 1).
32 M. de Lima et al. / Virology 390 (2009) 31–36and membrane-free form (Gonin et al., 1998; Mardassi et al., 1998). In
this context, the observed in vivo immunogenicity of GP3 has been
explained by its ability to be secreted from infected cells as previously
described (Mardassi et al., 1998). However, a structural role for GP3 in
PRRSV type II has been suggested by recent ﬁndings reporting its
ability to induce neutralizing antibodies (Cancel-Tirado et al., 2004;
Jiang et al., 2008). In addition, partial protective immunity was
observed in vivo by immunization of animals with a recombinant
baculovirus expressing ORF3 (Plana Duran et al., 1997) or with
recombinant fowlpox expressing GP3/GP5 (Shen et al., 2007). Overall,
it is evident that according to the available data, the structural nature
of the GP3 in PRRSV type II virions is still unclear and remains amatter
of controversy.
Glycoprotein 3 is the secondmost heterogeneous protein of PRRSV
with approximately 54 to 60% amino acid identity between North
American and European isolates (Meng et al., 1995). The protein
encoded by ORF3 is also the most glycosylated PRRSV protein with
seven putative N-linked glycosylation sites that are well conserved
among strains from both PRRSV serotypes (Gonin et al., 1998). Thus,
the predicted molecular mass (Mr) of the ORF3 protein (27–29 kDa) is
smaller than its apparent Mr estimated by gel electrophoresis (42–
50 kDa) (Dea et al., 2000; Gonin et al., 1998).
We herein present evidence that GP3 is incorporated into virus
particles of a North American strain of PRRSV (vFL12). Our results
indicate that GP3 represents just a small fraction of the structuralFig. 2. Radiolabeled viral suspension previously pelleted through a 30% sucrose cushion was
tube (determined in a scintillation counter) in the different fractions was determined. Fr
centrifuged and used for subsequent radioimmunoprecipitation experiments.proteins of PRRSV, which is consistent with the notion that GP3 is one
of the minor structural glycoproteins of the Arteriviridae (Meulenberg,
2000; Snijder and Meulenberg, 2001).
Results
Generation and characterization of GP3 monospeciﬁc antiserum
In order to conﬁrm the identity of GP3, we prepared an anti-GP3
monospeciﬁc antiserumby injecting rabbitswith two synthetic peptides
conjugated to KLH. Both 15 amino acid peptides within ORF3 protein
(Q61AAAEVYEPGRSLWC75 and S83EDDHDDLGFMVPG96C) were shown
to be highly immunogenic in our previous experiment as measured by
its reactivity with serum frompigs experimentally infectedwith a North
American strain of PRRSV (de Lima et al., 2006). An emulsion containing
both KLH-conjugated peptides emulsiﬁed in Freund's adjuvant were
injected in two rabbits at 2 weeks intervals. Speciﬁc anti-GP3 antiserum
was collected at 77 days after the ﬁrst injection, further characterized
and used in all experiments. Speciﬁcity of the anti-GP3 antiserum was
further conﬁrmed by an indirect immunoﬂuorescence staining of MARC
145 cells at about 48 h post infection with a PRRSV FL12 strain. A
cytoplasmic pattern of staining was observed when the anti-GP3
antiserum was used as a primary antibody followed by a secondary
anti-rabbit IgG antibody conjugated with Alexa Fluor 488 and observed
under confocal microscopy with nuclei stained with DAPI (data not
shown). No staining was observed following incubation of PRRSV-
infected MARC-145 cells with rabbit pre-immune serum (data not
shown).
The speciﬁcity of the anti-GP3monospeciﬁc antiserumwas further
investigated by radioimmunoprecipitation assays. The gene encoding
for GP3 protein of FL12 strain of PRRSV was PCR ampliﬁed and cloned
into pGEM3 expression vector using EcoRI and XhoI restriction sites.
The entire coding region was conﬁrmed by nucleotide sequencing.
Transfection followed by radioimmunoprecipitation using GP3 anti-
body revealed a clear protein species of ∼42–45 kDa (Fig. 1A, lane 2).
This particular signal was absent in the control lane which was
processed in a similar way, but in this case transfected with pGEM3
only. This data clearly indicates speciﬁc reactivity of generated GP3
antibody against PRRSV GP3 protein. In addition the anti-GP3
monospeciﬁc antiserum efﬁciently immunoprecipitated the GP3
from lysates of PRRSV-infected MARC-145 cells (Fig. 1B, lane 2). In
the same experiments several other distinct signals (27–29 kDa) were
also observed which most likely correspond to either partially
glycosylated forms of GP3 or co-immunoprecipitation of other viral
proteins i.e. GP2 and/or GP5.layered on a continuous sucrose gradient (20–60%) in TEN buffer. Virus titer and CPM/
actions 8–11 which correspond to the peak infectivity and CPM counts were pooled,
Fig. 3. A) Total protein derived from puriﬁed virus collected from a sucrose gradient
(fractions 8–11) were solubilized in RIPA buffer and analyzed by reducing SDS-PAGE
(12% gel). B) Radiolabeled and puriﬁed virions were subjected to immunoprecipitation
with GP3 monospeciﬁc antiserum (lane 2 — 70% of the lysate) or with a polyclonal
antibody anti-GP5 and a monoclonal antibody to M protein (lane 3— 20% of the lysate).
10% of the lysate was loaded onto lane 1. Immunoprecipitates were analyzed by
reducing SDS-PAGE (12% gel). Position of the size markers are indicated in the left and
positions of the PRRSV envelope proteins in the right side of the ﬂuorograms. (⁎)
Unidentiﬁed protein.
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major envelope proteins
In order to show that the GP3 was associated with the PRRSV type
II virion, we utilized a two-step puriﬁcation process of extracellular
virus. The ﬁrst round consisted of pelleting a clariﬁed supernatant
from PRRSV-infected MARC-145 cells containing radiolabeled virions
through a 30% sucrose cushion followed by a 20–60% (W/V) sucrose
gradient puriﬁcation of 35S-labeled virus. Fractions were carefully
collected from the top of the tube and used for titration, radioactivity
counting and immunoprecipitation experiments. Fractions containing
the highest infectivity titers and radioactive counts (fraction nos. 8–11,
Fig. 2) were used for subsequent experiments.
Initially, total proteins derived from the pooled fractions contain-
ing puriﬁed virus collected from a sucrose gradient were solubilized in
RIPA buffer and analyzed by reducing SDS-PAGE without addition of
antibody. We observed well deﬁned bands with molecular weights
corresponding to those reported for the major PRRSV structural
proteins (Fig. 3A). On the other hand, a small amount of a proteinwithFig. 4. Immunogold labeling of puriﬁed PRRSV particles with different antibodies. Puriﬁed v
anti-GP3 monospeciﬁc rabbit antiserum (C to G) or, anti-PRRSV rabbit polyclonal antibody (
correspond to 100 nm.a molecular weight of approximately 42–45 kDa was also clearly
observed in the lysate containing virion proteins.
In order to conﬁrm the identity of the above-mentioned 42–45 kDa
protein, the pooled fractions containing puriﬁed virions were
immunoprecipitated by incubation with anti-GP3 antibody and with
a pool of a polyclonal antibody anti-GP5 and amonoclonal antibody to
M protein (generated in our laboratory against a synthetic peptide
corresponding to a highly immunogenic linear epitope of M protein).
However, due to the small amount of 42–45 kDa protein visualized in
the gel (Fig. 3A), we used the majority of the lysate (70%) for
immunoprecipitation with anti-GP3 antibody, 20% of the lysate with
an anti-GP5 and anti-M antibody and the remaining 10% of lysate used
for loading as total protein (Fig. 3B). Using this strategy, a speciﬁc band
corresponding to GP3 was detected in pooled gradient fractions
containing puriﬁed virions by RIP with anti-GP3 antiserum (Fig. 3B,
lane 2). In addition, a faint band, most likely corresponding to GP2
and/or GP5 (27–29 kDa), was also co-precipitated by the anti-GP3
antibody.
Further evidence of the presence of GP3 at the level of PRRSV FL12
envelope was obtained by immunogold staining of the envelope of
puriﬁed virus present in the supernatant of infected cells with anti-
GP3 antiserum (Fig. 4). Puriﬁed virus was incubated with either pre-
immune rabbit serum (Fig. 4, panels A and B; as a negative control),
anti-GP3 monospeciﬁc rabbit antiserum (Fig. 4, panels C to G) and
anti-PRRSV rabbit polyclonal antibody (Fig. 4, panels H to J; as a
positive control) followed by an anti-rabbit IgG conjugated with gold
particles. No staining was observed when puriﬁed virions were
incubated with a PRRSV negative serum whereas a strong reactivity
was observed in virions incubated with a polyclonal antibody against
GP5 as shown by the number of gold particles surrounding the virus
envelope (Fig. 4, panels H to J). On the other hand, the number of gold
particles that were found associated with virions was clearly reduced
when incubated with the anti-GP3 monospeciﬁc antiserum (Fig. 4,
panels C to G).
Discussion
In the present study, we conﬁrmed the structural nature of GP3 in a
North American strain of PRRSV (vFL12). PRRSV vFL12 is recovered
from MARC-145 cells transfected with an infectious full-length cDNA
clone of PRRSV which has been extensively used in our laboratories
(Ansari et al., 2006; de Lima et al., 2006, 2008; Kwon et al., 2006,
2008; Truong et al., 2004). In previous studies, GP3 of PRRSV has been
shown to be incorporated into virions of European-type strains (van
Nieuwstadt et al., 1996), however such occurrence in PRRSV type IIirus was incubated with either pre-immune rabbit serum (A and B; negative control),
H to J) followed by an anti-rabbit IgG conjugated with gold particles. Black bars shown
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Mardassi et al., 1998). Since then, the notion that PRRSV type II virions
lacked GP3 prevailed.
In our study, RIP experiments conﬁrmed the speciﬁcity of the anti-
GP3 monospeciﬁc antiserum as measured by its reactivity with ORF3
protein either expressed by plasmid-transfected BHK-21 cells or by
PRRSVFL12-infectedMARC-145cells. Likewise, theGP3wasalsodetected
by indirect immunoﬂuorescence assay in the cytoplasm of methanol/
acetone-ﬁxed PRRSV-infected MARC-145 cells using the antiserum as a
primary antibody (data not shown). These ﬁndings unequivocally
demonstrated the ability of the anti-GP3 antibody to recognize the
ORF3 protein derived from the North American strain of PRRSV (FL12).
In order to demonstrate that association of the GP3with the PRRSV
type II virion, we used a puriﬁed preparation of 35S-labeled virus from
the supernatant of infected MARC-145 cells. By using a scintillation
counter, we observed a peak of radioactivity which corresponded to
the fractions 8–11 collected from the sucrose gradient. Interestingly,
viral titration of all fractions revealed the highest infectious titers in
these fractions, thus conﬁrming the presence of highly puriﬁed virions.
Pooled fractions were directly analyzed by SDS-PAGE or subjected to
RIP experiments using GP3 antibody. From these experiments, we
concluded that the GP3 was less abundant in puriﬁed virions than
other known structural proteins such as GP5 and M (Fig. 3). The
appearance of GP5 as a broad smear is consistentwith its incorporation
into virions as a mature glycoprotein with heterogeneous glycan
moieties. The co-precipitation of the M protein in these experiments
appears to be an inconsistent event and could possibly be related to the
experimental conditions or due to some interaction between the M
and GP3 protein. This type of unexpected co-precipitations amongst
PRRSV proteins were also reported byWu et al. (2005), who described
some interaction occurring between N and 2b proteins.
The amount of GP3 incorporated into PRRSV type II virions is clearly
lower when compared to the three major structural proteins N, M and
GP5. It could be speculated that only a small fraction of the protein is
incorporated into virions while other fraction(s) is (are) released into
the culture medium. A comparison of the staining intensities suggests
that the well-known major structural proteins such as M and GP5
predominate in the virion, while GP3 would be incorporated in
signiﬁcantly lower amounts. Thus, in order to clearly visualize the GP3,
a large amount of the lysate containing puriﬁed virions was required
whereas a large amount of GP5 was precipitated by the anti-GP5
polyclonal antibody in a fraction of just a smaller percentage of the
lysate. Similarly, analyses of the structural nature of GP3 and GP4 of
Lelystad virus required a large amount of virus to visualize these
proteins by immunostaining on the nitrocellulose strips (van Nieuw-
stadt et al., 1996). According to this data, we demonstrated that a
higher amount of lysate derived from puriﬁed virus is necessary to
visualize GP3 than the amount required to detect the major envelope
proteins like GP5 or M protein. This circumstance may, at least
partially, explain the unsuccessful detection of ORF3 protein incorpo-
rated into virions in a previous study reporting that GP3 from a North
American strain of PRRSV would not be part of the virion structure
(Gonin et al., 1998). Our results are also consistent with the detection
of a much fainter band corresponding to the ORF 2b protein when
compared to the amounts detected for GP5, M or N protein (Wu et al.,
2001). Collectively, this data indicates that the 42–45 kDa protein is an
integral but minor structural component of the PRRSV type II virion.
Immunogold staining of puriﬁed virus present in the supernatant of
infected cells with anti-GP3 antiserum provided further evidence of
the presence of GP3 at the level of PRRSV FL12 envelope (Fig. 4). While
no staining was observed in puriﬁed virions incubated with a PRRSV
negative serum, a strong reactivity was observed in virions incubated
with an anti-PRRSV polyclonal antibody as shown by the number of
gold particles surrounding the virus envelope (Fig. 4, panels H to J). On
the other hand, the number of gold particles that were found
associated with virions was clearly reduced when incubated with theanti-GP3 monospeciﬁc antiserum (Fig. 4, panels C to G). This ﬁnding
might be explained by the small amount of GP3 incorporated into
PRRSV virions.
The structural role for GP3 was suggested by recent ﬁndings
reporting the ability of the PRRSV GP3 to induce neutralizing
antibodies either alone or in combination with GP4 and GP5 (Jiang
et al., 2008). In addition, Cancel-Tirado et al. (2004) have demon-
strated that a monoclonal antibody to Gp3 was associated with
inhibition of PRRSV replication in porcine alveolar macrophages, thus
providing further evidence for a possible presence of neutralizing
epitopes in GP3. Recently the same laboratory has provided additional
evidence, by chimeric reverse genetics studies of PRRSV US type II,
that ORF3 contributes to the induction of neutralizing activity in
serums, together with ORF5 and 6 (Kim and Yoon, 2008). In addition,
partial protective immunity against PRRSV challenge was reported in
pregnant sows immunized with a recombinant baculovirus expres-
sing ORF3 from a Spanish strain of PRRS asmeasured by the number of
piglets born alive and healthy at the time of weaning (Plana Duran
et al., 1997). Pigs immunized with recombinant fowlpox expressing
GP3/GP5 developed a speciﬁc immune response against the PRRSV
proteins and most importantly, a degree of protection was also
conferred against challenge with a pathogenic strain of PRRSV (Shen
et al., 2007). Furthermore, it has also been reported that ORF3 encodes
a structural protein of Equine Arteritis virus (EAV). An additional
study showed that the minor envelope glycoproteins GP2b, GP3, and
GP4 of EAV form a heterotrimeric complex providing further evidence
that the GP3 homologous protein of EAV is structural (Wieringa et al.,
2004). Considering the homology among arteriviruses, other studies
have indicated that all seven structural proteins of EAV are required
for the production of infectious progeny virus (Molenkamp et al.,
2000; Snijder et al., 1999). Similar observations were also reported for
PRRSV LV strain. Some authors (Wissink et al., 2005) have shown that
all of PRRSV minor proteins interact with each other and they are
assembled into virions as a multimeric complex, thus being essential
for virus infectivity. Overall, this set of data substantiates our
observations indicating that GP3 is a minor structural component of
the PRRSV type II virions.
Materials and methods
Virus, cells and antibodies
FL12 strain is the PRRSV virus recovered from MARC-145 cells
transfected with RNA transcripts produced in vitro from the full-
length infectious cDNA clone (vFL12) derived from PRRSV NVSL 97-
7895 type II strain (GenBank accession no. AY545985) (Truong et al.,
2004). MARC-145 cells (Kim et al., 1993) were propagated in
Dulbecco's Modiﬁed Eagle's Medium (DMEM) containing 5–10%
fetal bovine serum (FBS) and antibiotics (100 U/ml of penicillin,
20 μg/ml of streptomycin, and 20 μg/ml of kanamycin) and were
used for viral multiplication and titration and for viral protein
expression. The BHK-21 cells were maintained in MEM containing 5%
fetal bovine serum (FBS) and antibiotics and used for transient
expression of GP3. Indirect immunoﬂuorescence assays (IFA) were
performed as previously described (Kwon et al., 2006) using PRRSV
N protein-speciﬁc monoclonal antibodies (MAbs): SDOW17
(National Veterinary Services Laboratories – NVSL, Ames, IA) and
SR30 [kindly provided by Dr. Eric Nelson (South Dakota State
University, SD, USA)]. The secondary antibody used in both cases
consisted of a goat antimouse IgG antibody (Alexa Fluor – 488,
Molecular Probes, Eugene, OR). For RIP experiments we used an anti-
GP5 polyclonal antibody (kindly provided by Dr Carl Gagnon,
University of Montreal) and an anti-M monoclonal antibody raised
against a synthetic peptide corresponding to a highly immunogenic
B-cell linear epitope of M protein (de Lima et al., 2006) and
previously characterized in our lab (data not shown).
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Based on previous studies in our laboratory (de Lima et al., 2006)
we selected two highly immunogenic 15-mer peptides based on the
glycoprotein 3 (GP3) amino acid sequence of a North American strain
of PRRSV (NVSL 97-7895). The peptides were synthesized and
conjugated to a carrier protein (KLH) either by adding a cysteine
residue or via activated EDC chemistry to its N-terminal region. The
amino acid residues of the selected peptides were Q61AAAE-
VYEPGRSLWC75 (cysteine originally found within the amino acid
sequence of GP3) and S83EDDHDDLGFMVPG96C (cysteine residue
added in order to facilitate its conjugation with KLH). These peptides
were selected for the antiserum preparation based on their observed
antigenicity and immunodominance in vivo (de Lima et al., 2006).
While no deﬁnitive knowledge exists about the topology of PRRSV
GP3, we would anticipate, based on previous knowledge of other
multi-glycosylated viral envelope proteins, that these peptides are
likely located in the ectodomain of PRRSV GP3.
Production of anti-GP3 monospeciﬁc rabbit antiserum
Two rabbits were used for this immunization; each receiving both
KLH-conjugated peptides emulsiﬁed in complete (once, ﬁrst shot) and
incomplete (several ensuing and successive shots) Freund's adjuvant.
Animals were co-immunized (solution containing both peptides) at
days 0, 14, 28, 42, 56 and 70. Bleedings were performed on days 49, 63
and 77 post immunization and serum samples tested for the presence
of anti-GP3 antibodies. Speciﬁc anti-GP3 monospeciﬁc antiserumwas
collected at 77 days after ﬁrst injection, characterized and used in all
experiments.
Expression of GP3 in BHK-21 cells
For transient expression of GP3, the BHK-21 cells were plated in six
well plates at 80% conﬂuency. The following day the cells werewashed
with PBS and infected with recombinant vaccinia virus (VTF7-3) at a
MOI of 3.0. Forty-ﬁve minutes after inoculation of the cultures, the
cells were washed with PBS again and DNA-Lipofectamine complex
(2.0 μg of plasmid DNA: 5.0 μl of Lipofectamine) was added to cells
according to manufacturer's protocol. The supernatant was replaced
with complete growth medium after 4 h post-transfection. At 16 h
post-transfection, the cells were washed with PBS and incubated with
Methionine- and Cysteine-free DMEM media to induce starvation.
After one hour, 50 μCi of S35 (Express Protein Labelling Mix, [35S],
Perkin Elmer) was mixed with 600 μl of Cys-Met free media, added
onto cells and further incubated for 4 h. Immunoprecipitation was
performed as described below.
Viral infection and metabolic labeling
Viral proteins derived from MARC-145 cells infected with PRRSV
FL12 strain and extracellular virions were labeled as follows: for
labeling of viral expressed intracellular GP3, the MARC-145 cells in six
well plates were infected with PRRSV FL12 strain at a M.O.I. of
approximately 1. At 18 h post infection (pi), cells were washed twice
with PBS and subjected to starvation in methionine/cysteine-free
DMEM for one hour. The starved cells were radiolabeled with 0.6 ml of
methionine/cysteine-free DMEM containing 100 μCi of S35 (Express
Protein Labelling Mix, [35S], Perkin Elmer) for 4 h and RIP was
performed as described below. For radiolabeling of extracellular
virions, conﬂuent monolayers of MARC-145 cells in 100 mm plates
were infected with PRRSV FL12 strain and, after 18 h, the infected cells
were labeled with 6.0 ml of 100 μCi of L-[35S] methionine/ml. In this
case the ﬁnal mediumwas composed of 90% of Cys-Met-free medium
and 10% of complete growth medium. Virus particles were labeled
overnight and the supernatant was collected and clariﬁed by lowspeed centrifugation. Radiolabeled PRRSV proteins and extracellular
virus were used in subsequent immunoprecipitation experiments.
Virus puriﬁcation
Above radiolabeled PRRSV virions were subjected to two rounds of
puriﬁcation. The clariﬁed supernatant from PRRSV FL12-infected
MARC 145 cells containing radiolabeled virus was ﬁrst pelleted
through a 30% sucrose cushion and then submitted to a 20–60%
(W/V) sucrose gradient overnight at 4 °C (100,000 g). Fractions were
carefully collected from the top of the tube and used for titration,
radioactivity counting and immunoprecipitation experiments.
Radioimmunoprecipitation and SDS-PAGE analysis
Immunoprecipitation experiments were performed with 1) BHK-
21 cells transfected with GP3 expressing plasmid vector, 2) radi-
olabeled proteins derived from MARC-145 cells infected with PRRSV;
and 3) radiolabeled extracellular virions as described elsewhere
(Ansari et al., 2006). Fractions with the highest infectivity and CPM
counting were pooled and used for subsequent RIP experiments.
Brieﬂy, radiolabeled puriﬁed virus or cell extracts were resuspended
in RIPA buffer (10 mM Tris–HCl pH 8.0, 150 mM NaCl, 1% Triton X-100,
0.1% SDS, 1% Sodium deoxycholate, and 1× protease inhibitor). The
clariﬁed supernatants were incubated with anti-GP3 polyclonal
antibody or with a pool of anti-GP5 and anti-M antibodies (1:100
dilutions) for 16 h at 4 °C with shaking. Approximately 3.0 μg of
constituted Protein A Sepharose (Protein A Sepharose™ CL-48, GE
Health care Bio-science AB) was added per tube and further incubated
at 4 °C for two hours. The immune complexes were centrifuged at
10,000 rpm for 30 s andwashed with RIPA buffer three times with ﬁve
minute incubation, each time keeping the samples in a rotator at 4 °C.
Finally the immune complexes were resuspended in 2× sample buffer
and boiled for ﬁve minutes. The samples were again centrifuged
brieﬂy and the supernatants were analyzed by SDS-12% PAGE gel. The
gel was ﬁxed with 10% acetic acid for 15 min, washed three times with
distilled water, treated with 0.5 M sodium salicylate for 30 min, dried
and ﬁnally exposed to X-ray ﬁlm at −70 °C.
Immunogold staining
Brieﬂy, after two rounds of low speed centrifugation, the clariﬁed
supernatant of PRRSV-infectedMARC-145 cells was pelleted through a
30% sucrose cushion by ultracentrifugation (25,000 rpm) for 2 h.
Puriﬁed virus suspension was placed onto a formvar-carbon coated
copper grid (duplicate grids were used for each experiment) for
approximately 1 min. Each grid was then placed on a drop of 5%BSA in
PBS for 10 min. After, the samples were incubated with an anti-GP3
monospeciﬁc rabbit antiserum for 30 min. Pre-immune rabbit serum
was used as a negative control and anti-PRRSV rabbit polyclonal
hyperimmune serum (obtained by repeated immunizations of rabbits
using supernatant and lysates of PRRSV-infected MARC-145 cells) as a
positive control. All antibodies were diluted in PBS with 5% BSA. The
samples were then washed three times of ﬁve minutes each with PBS
and incubated with an anti-rabbit IgG conjugated with 10 nm gold
particles. After another washing step, the samples were ﬁxed in 3%
glutaraldehyde in 0.1 M cacodylate buffer, negative-stained on a drop
of 1% sodium silicotungstate and observed under electron microscopy.
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